Drugs / 124I-cRGDY-PEG-dots
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT01266096 | Jan 2011 → Dec 2026 expected | brain cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 124I-cRGDY-PEG-dots | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01266096 ↗ |
| Modality | Diagnostic / imaging agent | “hybrid PET-optical imaging agents” PMID 25355699 ↗ Oct 2014 |
| Route | Intravenous | “after intravenous administration in patients” PMID 25355699 ↗ Oct 2014 |